THE GIST
China's demographic headache is quietly padding dairy balance sheets. Enter New Zealand's A2 Milk Company, the Wellington-listed formula maker that avoids the A1 protein and leans hard into "premium." It just posted strong earnings, beating analyst estimates, thanks to China's push to boost births while also caring for a rapidly aging population. Conveniently, A2's formula caters to both ends of the age spectrum.
WHAT HAPPENED
Two forces are driving A2 Milk's China boom: Beijing's campaign to lift the birth rate and a lingering distrust of the domestic dairy industry.
A2 reported a 20.3% jump in revenue, powered largely by demand in China and other Asian markets. Infant formula sales climbed sharply and accounted for a growing share of overall growth. The stock jumped 11.7% to NZ$11.17, its highest level since February 24, 2021, before closing up 5% on the day.
Zoom out and the trajectory is even wilder. Over the past decade, A2's market cap has grown from $258 million to roughly $4.7 billion. That's about $4.4 billion in value creation, an 18x expansion at its peak. Asia did the heavy lifting. China alone accounts for roughly 68% of revenue.
WHY IT MATTERS
China is rolling out targeted programs to lift birth rates, including subsidies for baby formula and preschool education. Whether those policies can reverse long-term fertility decline is an open question. A2 doesn't need a baby boom to win. It just needs steady demand from anxious parents and health-conscious adults.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
The company markets its milk as containing only A2 beta-casein protein, which it says is easier to digest than conventional milk with A1 protein. That pitch travels well. It resonates with parents, pregnant women, adults with digestive sensitivities, and seniors.
There's also history here. After a series of adulteration scandals, Chinese consumers developed deep distrust of parts of the domestic dairy industry. Infant formula is subject to stricter regulation than ordinary milk powder. Imported brands such as A2 are viewed as safer and more tightly controlled. That perception extends beyond toddlers. In China, premium infant formula is often consumed well past infancy. Adults buy it for purity, safety, and nutritional quality.
China also has a strong appetite for "functional" foods, and formula powder is convenient and shelf-stable. Two years ago, A2 launched China-label fortified adult milk powder designed to support immune function, as well as bone, joint, and muscle health in older consumers. The same brand that promises digestive comfort for babies now promises joint support for their grandparents. Vertical integration, family edition.
WHAT'S NEXT
A2 isn't alone. Nestlé, Danone, New Zealand's Fonterra, and Abbott Laboratories are all positioned to benefit from China's demographic strategy, selling to new parents while also targeting seniors.
China's birth rate may tick up or continue sliding. Either way, premium dairy brands have built a business model around demographic anxiety. When a country worries about having too few babies and too many retirees at the same time, someone ends up selling milk to both.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
